Gossamer Bio (NASDAQ:GOSS – Free Report) had its price objective decreased by Wedbush to $32.00 in a research note released on Wednesday morning, MarketBeat Ratings reports. Wedbush currently has a neutral rating on the stock.
Several other equities analysts have also recently weighed in on GOSS. Chardan Capital reaffirmed a “buy” rating on shares of Gossamer Bio in a research report on Monday, October 26th. Weiss Ratings downgraded Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $246.40.
View Our Latest Analysis on GOSS
Gossamer Bio Stock Down 2.4%
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($7.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.79) by ($3.57). The firm had revenue of $38.43 million during the quarter, compared to the consensus estimate of $12.16 million. Research analysts anticipate that Gossamer Bio will post -27.13 EPS for the current year.
Hedge Funds Weigh In On Gossamer Bio
Several institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in Gossamer Bio in the 2nd quarter worth about $2,467,000. Kalehua Capital Management LLC purchased a new position in Gossamer Bio during the first quarter worth about $3,363,000. ARCH Venture Management LLC purchased a new position in Gossamer Bio during the second quarter worth about $1,326,004. BlackRock Inc. purchased a new position in Gossamer Bio during the second quarter worth about $1,262,000. Finally, Corient Private Wealth LP increased its stake in Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after acquiring an additional 1,647,315 shares during the last quarter. 81.23% of the stock is owned by institutional investors.
About Gossamer Bio
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Featured Articles
- Five stocks we like better than Gossamer Bio
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
